---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001777"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2022-02-23T23:59:59+00:00"
generated_at: "2026-06-27T05:33:58.877042+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences reports Q4 net income of $279.4M on Gilead option exercise; cash ~$1.4B post-Gilead payments

## Summary
- Q4 2021 revenue $354.5M (vs $9.5M Q4 2020) primarily from Gilead license revenue; full-year revenue $382.9M.
- Net income Q4 $279.4M vs net loss $51.9M prior year; full-year net income $52.8M vs net loss $122.9M.
- Cash, equivalents and investments $681.3M at Dec 31, 2021; plus $725M from Gilead in Jan 2022 = ~$1.4B, funding into 2026.
- First patient dosed in PACIFIC-8 Phase 3 (domvanalimab + durvalumab in Stage 3 NSCLC); two more Phase 3 studies planned for 2022.
- Data readouts for ARC-7 (domvanalimab/etrumadenant in NSCLC) and ARC-8 (quemliclustat in pancreatic cancer) expected 2H22.

## SEC filing metadata
- accession: 0000950170-22-001777
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2022-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017022001777/0000950170-22-001777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017022001777/rcus-20220223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001777
- JSON: https://secwatch.observer/filing/0000950170-22-001777.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.